BEONE MEDICINES AUS

Company snapshot

BEONE MEDICINES AUS maintains 122 tracked programs across Advanced Solid Tumor, Chronic Lymphocytic Leukemia, Solid Tumor, Adult, Mantle Cell Lymphoma, Previously Untreated Chronic Lymphocytic Leukemia, Advanced Solid Tumors, Non-Small Cell Lung Cancer, Breast Cancer, Mature B-cell Malignancies, Urothelial Carcinoma, previously untreated chronic lymphocytic leukemia (CLL), Relapsed or Refractory B

• 4 approved product(s) across US/EU regulatory metadata.
• 122 active pipeline program(s) linked via ClinicalTrials.gov.
• 122 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for BEONE MEDICINES AUS. Not investment advice.

• deal Jun 2, 2026

  BeOne Medicines' HERIZON-GEA Phase 3 Data in NEJM: A Deep Dive for Pharma BD and Investors

• approval Jun 2, 2026

  ASCO26: Summit, Akeso claim OS victory for ivonescimab in pivotal Chinese study

• Peer + 0 momentum

  AstraZeneca

  TA overlap score 50

• Peer + 0 momentum

  HOFFMANN-LA ROCHE

  TA overlap score 40

• Peer + 0 momentum

  Eikon Therapeutics

  TA overlap score 33

• Peer + 0 momentum

  Eli Lilly and

  TA overlap score 32.4

• Peer + 0 momentum

  Daiichi Sankyo US

  TA overlap score 31.6

• Peer + 0 momentum

  PUMA BIOTECHNOLOGY

  TA overlap score 28

• Peer + 0 momentum

  BridgeBio Oncology Therapeutics

  TA overlap score 26.8

• Peer + 0 momentum

  ADC Therapeutics

  TA overlap score 26

• Peer + 0 momentum

  Genmab

  TA overlap score 25.8

• Peer + 0 momentum

  Revolution Medicines

  TA overlap score 25.2

Recent activity

Latest pipeline, patent, and corporate events for BEONE MEDICINES AUS.

1. Jun 8, 2026 Clinical update

   A Phase 1a/1b for Advanced, metastatic or unresec… — Phase 1

2. Jun 8, 2026 Clinical update

   A Phase 1a/b Study Investigating the Safety for Advanced, or metastatic solid t… — Phase 1

3. Jun 8, 2026 Clinical update

   BFH-NCRTPD — Phase 2

4. Jun 8, 2026 Clinical update

   BGB-A317-290-LTE1 — Phase 3

5. Jun 8, 2026 Clinical update

   BGB-43395-101 — Phase 1

View all clinical trial activity →

• What is BEONE MEDICINES AUS?

  BEONE MEDICINES AUS is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Advanced Solid Tumor, Chronic Lymphocytic Leukemia, Solid Tumor, Adult, Mantle Cell Lymphoma, Previously Untreated Chronic Lymphocytic Leukemia. NovaPharmaNews li

• Is BEONE MEDICINES AUS publicly traded?

  BEONE MEDICINES AUS appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does BEONE MEDICINES AUS develop or market?

  We link 63 drug profile(s) where BEONE MEDICINES AUS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/beone-medicines#company-drugs.

• What are the latest developments for BEONE MEDICINES AUS?

  In the last 12 months our linked public records show 122 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does BEONE MEDICINES AUS focus on?

  BEONE MEDICINES AUS focuses on Advanced Solid Tumor, Chronic Lymphocytic Leukemia, Solid Tumor, Adult based on our analysis of their pipeline programs and drug development activities.